Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities

Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million (unaudited) Company reaffirms peak U.S. net IBSRELA sales revenue of greater than$1 Billion Company announces peak U.S. net XPHOZAH sales revenue of $750 million Company finishes 2024 with approximately$250 million in cash, cash equivalents and investments (unaudited) WALTHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical c ...